Pfizer Inc (PFE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pfizer Inc stock (PFE) is currently trading at $27.28. Pfizer Inc PE ratio is 19.82. Pfizer Inc PS ratio (Price-to-Sales) is 2.45. Analyst consensus price target for PFE is $28.58. WallStSmart rates PFE as Underperform.
- PFE PE ratio analysis and historical PE chart
- PFE PS ratio (Price-to-Sales) history and trend
- PFE intrinsic value — DCF, Graham Number, EPV models
- PFE stock price prediction 2025 2026 2027 2028 2029 2030
- PFE fair value vs current price
- PFE insider transactions and insider buying
- Is PFE undervalued or overvalued?
- Pfizer Inc financial analysis — revenue, earnings, cash flow
- PFE Piotroski F-Score and Altman Z-Score
- PFE analyst price target and Smart Rating
Pfizer Inc
📊 No data available
Try selecting a different time range
PFE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Pfizer Inc (PFE)
PFE trades 195% above its Graham fair value of $9.25, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Pfizer Inc (PFE) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, price/book. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Pfizer Inc (PFE) Key Strengths (4)
Large-cap company with substantial market presence
Strong operational efficiency: $24 kept per $100 revenue
Trading at 1.77x book value, attractively priced
67.73% held by institutions, strong professional interest
Supporting Valuation Data
Pfizer Inc (PFE) Areas to Watch (6)
Revenue declining -1.20%, a shrinking business
Earnings declining -21.30%, profits shrinking
Very expensive relative to growth, significant premium
Low profitability relative to shareholder equity
Revenue is fairly priced at 2.45x sales
Decent profitability, keeps $12 per $100 revenue
Pfizer Inc (PFE) Detailed Analysis Report
Overall Assessment
This company scores 49/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.3/10) while 6 fall into concern territory (avg 2.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, Operating Margin, Price/Book. Valuation metrics including Price/Book (1.77) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 23.90%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, PEG Ratio. Some valuation metrics including PEG Ratio (13.77), Price/Sales (2.45) suggest expensive pricing. Growth concerns include Revenue Growth at -1.20%, EPS Growth at -21.30%, which may limit upside. Profitability pressure is visible in Return on Equity at 8.89%, Profit Margin at 12.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 8.89% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -1.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PFE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PFE's Price-to-Sales ratio of 2.45x trades 26% below its historical average of 3.33x (23th percentile). The current valuation is 53% below its historical high of 5.18x set in Nov 2018, and 40% above its historical low of 1.75x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pfizer Inc (PFE) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Pfizer Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 62.6B with 120% decline year-over-year. Profit margins of 12.4% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 889.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 4.5B in free cash flow and 5.3B in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 120% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can Pfizer Inc push profit margins above 15% as the business scales?
Dividend sustainability with a current yield of 6.4%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Pfizer Inc.
Bottom Line
Pfizer Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(55 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BOURLA, ALBERT Director, Chairman & CEO | Buy | +1,630 |
| Insider | Type | Shares |
|---|---|---|
DAMICO, JENNIFER B. SVP & Controller | Sell | -826 |
| Insider | Type | Shares |
|---|---|---|
DAMICO, JENNIFER B. SVP & Controller | Sell | -655 |
| Insider | Type | Shares |
|---|---|---|
MCDERMOTT, MICHAEL Executive Vice President | Sell | -3,503 |
| Insider | Type | Shares |
|---|---|---|
BOURLA, ALBERT Director, Chairman & CEO | Buy | +2,883 |
| Insider | Type | Shares |
|---|---|---|
BOSHOFF, CHRISTOFFEL President, R&D | Sell | -12,887 |
| Insider | Type | Shares |
|---|---|---|
BOURLA, ALBERT Director, Chairman & CEO | Buy | +79 |
Data sourced from SEC Form 4 filings
Last updated: 8:22:27 AM
About Pfizer Inc(PFE)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.